» Articles » PMID: 2959663

Absorptive-mediated Endocytosis of Cationized Albumin and a Beta-endorphin-cationized Albumin Chimeric Peptide by Isolated Brain Capillaries. Model System of Blood-brain Barrier Transport

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1987 Nov 5
PMID 2959663
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Cationized albumin (pI greater than 8), unlike native albumin (pI approximately 4), enters cerebrospinal fluid (CSF) rapidly from blood. This suggests that a specific uptake mechanism for cationized albumin may exist at the brain capillary wall, i.e. the blood-brain barrier. Isolated bovine brain capillaries rapidly bound cationized [3H]albumin and approximately 70% of the bound radioactivity was resistant to mild acid wash, which is assumed to represent internalized peptide. Binding was saturable and a Scatchard plot gave a maximal binding capacity (Ro) = 5.5 +/- 0.7 micrograms/mgp (79 +/- 10 pmol/mgp), and a half-saturation constant (KD) = 55 +/- 8 micrograms/ml (0.8 +/- 0.1 microM). The binding of cationized [3H]albumin (pI = 8.5-9) was inhibited by protamine, protamine sulfate, and polylysine (molecular weight = 70,000) with a Ki of approximately 3 micrograms/ml for all three proteins. The use of cationized albumin in directed delivery of peptides through the blood-brain barrier was examined by coupling [3H]beta-endorphin to unlabeled cationized albumin (pI = 8.5-9) using the bifunctional reagent, N-succinimidyl 3-(2-pyridyldithio)proprionate. The [3H]beta-endorphin-cationized albumin chimeric peptide was rapidly bound and endocytosed by isolated bovine brain capillaries, and this was inhibited by unlabeled cationized albumin but not by unconjugated beta-endorphin or native bovine albumin. Cationized albumin provides a new tool for studying absorptive-mediated endocytosis at the brain capillary and may also provide a vehicle for directed drug delivery through the blood-brain barrier.

Citing Articles

Drug delivery strategies with lipid-based nanoparticles for Alzheimer's disease treatment.

Jang Y, Kang S, Park H, Lee D, Kim J, Kim J J Nanobiotechnology. 2025; 23(1):99.

PMID: 39930497 PMC: 11809104. DOI: 10.1186/s12951-025-03109-3.


Enhancing Antibody Exposure in the Central Nervous System: Mechanisms of Uptake, Clearance, and Strategies for Improved Brain Delivery.

Schwinghamer K, Siahaan T J Nanotheranostics. 2025; 4(4):463-479.

PMID: 39897432 PMC: 11784990. DOI: 10.3390/jnt4040020.


γ-Glutamyl transpeptidase-activable nanoprobe crosses the blood-brain barrier for immuno-sonodynamic therapy of glioma.

Li B, Chen G, Zhong H, Li T, Lin M, Wei H Nat Commun. 2024; 15(1):10418.

PMID: 39613729 PMC: 11607351. DOI: 10.1038/s41467-024-54382-z.


Anchoring Microbubbles on Cerebrovascular Endothelium as a New Strategy Enabling Low-Energy Ultrasound-Assisted Delivery of Varisized Agents Across Blood-Brain Barrier.

Li B, Lin Y, Chen G, Cai M, Zhong H, Xiao Z Adv Sci (Weinh). 2023; 10(33):e2302134.

PMID: 37870165 PMC: 10667842. DOI: 10.1002/advs.202302134.


Drug Permeability: From the Blood-Brain Barrier to the Peripheral Nerve Barriers.

Sun Y, Zabihi M, Li Q, Li X, Kim B, Ubogu E Adv Ther (Weinh). 2023; 6(4).

PMID: 37649593 PMC: 10465108. DOI: 10.1002/adtp.202200150.